This study aims to compare the effects of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate for treatment of hyperkalemia in patients undergoing regular hemodialysis.
Patients maintained on regular hemodialysis (HD) have a high risk of hyperkalemia (\>5.0 mmol/l). Hyperkalemia is a critical medical condition that can result in arrhythmias and sudden cardiac death. Treatment of hyperkalemia in HD patients is challenging. Therapeutic options for the treatment of hyperkalemia in HD population include potassium binding resins, such as sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate. There is limited data about the use of these agents in HD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
Faculty of Medicine, Aexandria University
Alexandria, Egypt
Change in serum potassium
By assessing serum K at baseline, 24 hrs after first dose, then weekly after the long interdialytic interval
Time frame: 8 weeks
Change in interdialytic weight
By assessing change in interdialytic weight
Time frame: 8 weeks
Gastrointestinal side effects
By reporting any GIT SE
Time frame: 8 weeks
Change in Blood pressure
systolic and diastolic Blood pressure change
Time frame: 8 weeks
Serious adverse events
By reporting any serious adverse events.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.